Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

App aims to improve life for brain tumor patients

NCT ID NCT07439302

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test whether a mobile app called Resilience PRO can help monitor symptoms and quality of life in 80 adults with IDH-mutated glioma who are starting a new systemic treatment. Participants will use the app to report side effects and complete questionnaires every two weeks. The goal is to see if remote monitoring can catch problems early and improve care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Resilience PRO mobile app for symptom monitoring
What this could lead to
If successful, this could show that remote symptom tracking improves quality of life and reduces hospital visits for people with this type of brain tumor.
What could go wrong
This is an observational study, not a treatment trial. It may not prove that the app directly improves outcomes, and results may vary across different patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults (over 18 years of age) 2. Written consent from the patient to participate in the clinical study 3. Diagnosed with grade 2-4 glioma with IDH1/2 mutation 4. Plan to initiate new systemic treatment for glioma (chemotherapy, targeted therapy, or other investigational antitumor systemic agent) 5. Candidate for ePRO monitoring using Resilience PRO medical device according to local investigator decision 6. Social security coverage Exclusion Criteria: 1. Severe language impairment 2. Cognitive deficit preventing the understanding of essential elements for questionnaires 3. Patient under guardianship or curatorship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glioma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA Oncology

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Service de Neuro-oncologie, Hôpital de la Pitié-Salpêtrière

    Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.